Regulatory approval

Published by the Health Service Executive. Approved

Treatment of adults with previously treated anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC).

This is written in the approval document.

Reimbursement

CDS

Citation

Crizotinib Monotherapy, 2025, version number 7, NCCP National SACT Regimen, NCCP, viewed 26/03/2026, https://healthservice.hse.ie/documents/6934/243_V7_Crizotinib_Monotherapy.pdf

View API

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Organizations Biomarkers Cancer types Therapies
HSE (1) v::ALK Non-Small Cell Lung Cancer Crizotinib